List of bibliographic references
Number of relevant bibliographic references: 13.
| Ident. | Authors (with country if any) | Title |
|---|
| 000068 (2012) |
Yee Chiu [Royaume-Uni] ; Andrew J. K. Ostor [Royaume-Uni] ; Anthony Hammond [Royaume-Uni] ; Katharina Sokoll [Royaume-Uni] ; Marina Anderson [Royaume-Uni] ; Maya Buch [Royaume-Uni] ; Michael R. Ehrenstein [Royaume-Uni] ; Patrick Gordon [Royaume-Uni] ; Sophia Steer [Royaume-Uni] ; Ian N. Bruce [Royaume-Uni] | Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales |
| 000099 (2010) |
Chi Chiu Mok [Hong Kong] ; Lai Shan Tam [Hong Kong] ; Tak Hin Chan [Hong Kong] ; Gavin K. W. Lee [Hong Kong] ; Edmund K. M. Li [Hong Kong] | Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology |
| 000300 (2012) |
Joerg-Patrick Stübgen [États-Unis] | Targeted immunotherapy trials for idiopathic inflammatory myopathies |
| 000343 (2007) |
Norihiro Nishimoto [Japon] ; Jun Hashimoto [Japon] ; Nobuyuki Miyasaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Shinichi Kawai [Japon] ; Tsutomu Takeuchi [Japon] ; Norikazu Murata [Japon] ; Désirée Van Der Heijde [Pays-Bas] ; Tadamitsu Kishimoto [Japon] | Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab |
| 000748 (2012) |
Ariel C. Bulua [États-Unis] ; Douglas B. Mogul [États-Unis] ; Ivona Aksentijevich [États-Unis] ; Harjot Singh [États-Unis] ; David Y. He [États-Unis] ; Larry R. Muenz [États-Unis] ; Michael M. Ward [États-Unis] ; Cheryl H. Yarboro [États-Unis] ; Daniel L. Kastner [États-Unis] ; Richard M. Siegel [États-Unis] ; Keith M. Hull [États-Unis] | Efficacy of etanercept in the tumor necrosis factor receptor–associated periodic syndrome: A prospective, open‐label, dose‐escalation study |
| 000829 (2013) |
K. Michaud ; S. Pedro ; T. Simon [États-Unis] ; F. Wolfe | FRI0250 Are rheumatoid arthritis patients who receive abatacept comparable with those on other biologics? |
| 000980 (2013) |
V. Rosario [Espagne] ; M. V. Hernández [Espagne] ; J. Inciarte-Mundo [Espagne] ; V. Ruiz-Esquide [Espagne] ; S. Cabrera [Espagne] ; M. E. G Mez [Espagne] ; J. A. G Mez-Puerta [Espagne] ; J. Ramírez [Espagne] ; J. D. Ca Ete [Espagne] ; R. Sanmartí [Espagne] | AB0500 A significant number of patients with rheumatoid arthritis receive low doses of biological agents in clinical practice |
| 000B05 (2012) |
T. Magnus [Allemagne] ; A. Melms [Allemagne] ; I. Kötter [Allemagne] ; J. U. Holle [Allemagne] | Neurologische Manifestationen von Vaskulitiden und primäre ZNS-Vaskulitis |
| 000B44 (2012) |
W. Rigby [États-Unis] ; H. Tony [Allemagne] ; K. Oelke [États-Unis] ; B. Combe [France] ; A. Laster [États-Unis] ; C. A. Von Muhlen [Brésil] ; E. Fisheleva [Royaume-Uni] ; C. Martin [Royaume-Uni] ; H. Travers [Royaume-Uni] ; W. Dummer [États-Unis] | Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty‐eight–week randomized, double‐blind, placebo‐controlled, parallel‐group phase III trial |
| 000D04 (2010) |
S. A. Polyzos [Grèce] ; A. D. Anastasilakis [Grèce] ; C. Bratengeier [Autriche] ; W. Woloszczuk [Autriche] ; A. Papatheodorou [Grèce] ; E. Terpos [Grèce] | Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide |
| 001247 (2012) |
P. P. Tak [Pays-Bas] ; P. J. Mease [États-Unis] ; M. C. Genovese [États-Unis] ; J. Kremer [États-Unis] ; B. Haraoui [Canada] ; Y. Tanaka [Japon] ; C. O. Bingham Iii [États-Unis] ; A. Ashrafzadeh [États-Unis] ; H. Travers [Royaume-Uni] ; S. Safa-Leathers [Royaume-Uni] ; S. Kumar [Royaume-Uni] ; W. Dummer [États-Unis] | Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty‐eight–week randomized, double‐blind, placebo‐controlled, parallel‐group phase III trial |
| 001263 (2012) |
Michael Yellin [États-Unis] ; Igor Paliienko [Ukraine] ; Andra Balanescu [Roumanie] ; Semen Ter-Vartanian [Ukraine] ; Vira Tseluyko [Ukraine] ; Li-An Xu [États-Unis] ; Xiaolu Tao [États-Unis] ; Pina M. Cardarelli [États-Unis] ; Heidi Leblanc [États-Unis] ; Geoff Nichol [États-Unis] ; Codrina Ancuta [Roumanie] ; Rodica Chirieac [Roumanie] ; Allison Luo [États-Unis] | A phase II, randomized, double‐blind, placebo‐controlled study evaluating the efficacy and safety of MDX‐1100, a fully human anti‐CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis |
| 001478 (2005) |
J J Cush | Biological drug use: US perspectives on indications and monitoring |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation
HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i -k "receive"
HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i \
-Sk "receive" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Istex
|étape= Curation
|type= indexItem
|index= AbsEn.i
|clé= receive
}}
| This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021 |  |
